WO2001090390A9 - Use of baculovirus vectors in gene therapy - Google Patents
Use of baculovirus vectors in gene therapyInfo
- Publication number
- WO2001090390A9 WO2001090390A9 PCT/GB2001/002383 GB0102383W WO0190390A9 WO 2001090390 A9 WO2001090390 A9 WO 2001090390A9 GB 0102383 W GB0102383 W GB 0102383W WO 0190390 A9 WO0190390 A9 WO 0190390A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- gene
- baculovirus
- baculoviruses
- delivery
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- This invention relates to gene delivery using a viral vector.
- Efficient gene transfer would be a beneficial tool for the treatment of vascular diseases, such as post-angioplastyrestenosis, post-bypass atherosclerosis, peripheral atherosclerotic disease, stenosis of vascular prosthesis anastomoses, and thrombus formation.
- vascular diseases such as post-angioplastyrestenosis, post-bypass atherosclerosis, peripheral atherosclerotic disease, stenosis of vascular prosthesis anastomoses, and thrombus formation.
- vascular diseases such as post-angioplastyrestenosis, post-bypass atherosclerosis, peripheral atherosclerotic disease, stenosis of vascular prosthesis anastomoses, and thrombus formation.
- Various techniques have been developed for this purpose; see, for example, Yla-Herttuala et al, J. Clin. Invest. 95:2692
- WO-A-98/20027 discloses a periadventitial collar that can be used for arterial gene transfer during vascular surgery.
- WO-A-98/20027 discloses a periadventitial collar that can be used for arterial gene transfer during vascular surgery.
- Baculoviruses have long been used as biopesticides and as tools for efficient recombinant protein production in insect cells. They are generally regarded as safe, due to the naturally high species specificity and because they are not known to propagate in any non-invertebrate host. Although the virions have been shown to enter certain cell lines derived from vertebrate species, no evidence of viral gene expression has been detected using natural viruses. However, the Autographa californica multiple nuclear polyhedrosis virus (AcMNPV), containing an appropriate eukaryotic promoter, is able to transfer and express target genes efficiently in several mammalian cell types; see, for example, Hofmann et al, PNAS USA 92:10099-10103 (1995).
- AcMNPV Autographa californica multiple nuclear polyhedrosis virus
- baculovirus having the vesicular stomatitis virus C glycoprotein in its envelope significantly increases the efficiency of transduction of human hepatoma cell lines and broadens the range of mammalian cell types that can be transduced by baculoviruses.
- Stable transduction of mammalian cells by baculoviruses has been achieved by either including an expression cassette encoding a dominant selectable marker into baculovirus genome or by using hybrid baculovirus-adeno-associated virus vector; see Condreay etal, PNAS USA 96:127-132 (1999), and Palombo etal, J. Virol. 72:5025-34 (1998).
- WO-A-00/05394 discloses baculovirus vectors and their use for gene transfer to the nerve cells of vertebrates. Summary of the Invention
- baculoviruses are able to mediate periadventitial gene transfer to rabbit carotid arteries with an efficiency comparable to adenoviruses.
- This invention is able to use the advantageous properties of baculoviruses, in a suitable vector, from which the gene is expressed, if administered (in or ex vivo) to a body site at which there is no blood, or which is essentially free of blood.
- baculoviruses in a suitable vector, from which the gene is expressed, if administered (in or ex vivo) to a body site at which there is no blood, or which is essentially free of blood.
- collar-mediated local gene delivery allows gene transfer essentially in the absence of serum, thus avoiding deleterious effects of serum components.
- the novel method also avoids two other major problems encountered in systemic gene delivery, i.e. a rapid redistribution of the virus from the injection site and a drop in the local concentration of the virus.
- Suitable delivery systems, active materials, formulations, dosages etc, are illustrated in WO-A-98/20027 and also WO-A-99/55315 (the contents of which are incorporated herein by reference).
- the delivery vehicle may be a collar or wrap.
- the vector for gene delivery is a baculovirus.
- Baculoviruses are of course known, and the skilled person will be able to construct any suitable vector for use in this invention. It will also be evident that the broad knowledge of baculovirus biology and AcMNPV genome will aid engineering of the improved second-generation viruses for gene transfer applications. The ease of construction, and capacity to accept large foreign DNA-fragments (>20 kbp), allows the development of baculoviruses having enlarged or targeted cell tropism along with more stable, temporal and cell type-specific control of transgene expression. A recombinant baculovirus for use in the invention may be formulated into a medicament for therapeutic use, in known manner.
- Routes and sites of administration for the invention include intra-ocular application, intra-articular application, superficial intra-dermal application, ureters, bladder, Fallopian tubes, gall bladder, spinal cord, cerebrospinal fluid compartment, pleural cavity and intraperitoneal cavity.
- Sites that have been used are arteries, brain and skeletal muscle, including, by way of example, mycocytes, satellite cells and regenerating myoblasts.
- Gene delivery may be done via direct injection or various types of catheters.
- body parts can be made "bloodless" during surgery. This technique is often used in leg or arm surgery by putting tight pressure around arm or thigh, thus preventing blood flow. The body part may then be perfused with saline to remove blood, and baculovirus transfection can then be done.
- the invention can be used for the delivery of an agonist of a VEGF receptor, e.g. described in more detail in WO-A-98/20027. Further, by suitable choice of the gene, it may be used in the treatment of cancer, e.g. in the brain.
- a further aspect of the invention relates to transplant organs and vessels which can be perfused with saline ex vivo and subjected to ex vivo baculovirus injection.
- the following experimental work illustrates the invention.
- Viruses were constructed by using the transfer vector pFASTBad (pFB) (Gibco) (Gibco).
- ⁇ nt -Gal cassette with a cytomegalovirus (CMV) promoter was inserted into the Stu ⁇ site of pFB in reverse orientation with respect to the polyhedrin promoter, generating plasmid pFBCMV- ⁇ nt .
- CMV cytomegalovirus
- Recombinant viruses were generated by using a BacTo-BacTM Baculovirus Expression System (Gibco BRL). Viruses were amplified in Spodoptera frugiperda 9 (Sf9) suspension cultures (SF-900 medium, Gibco BRL) for 3 days using cell density of 2 x 10 6 cells/ml. For 50 ml of culture, 200 ⁇ l of primary transfection supernatant was used as an inoculum. To obtain 1 litre of amplified virus, 2 ml of amplified virus stock was used as an inoculum. The cell culture medium was centrifuged at 16,000 g for 20 min at room temperature to remove cell debris.
- the clarified supernatant was transferred to ultracentrifuge tubes underlaid with 1.5 ml of 25% sucrose in phosphate- buffered saline (PBS) and the viruses were concentrated by centrifugation (120,000 g, 4°C, 1.5 h).
- the virus pellets were resuspended into 35 ml of ice-cold PBS, transferred into ultracentrifuge tubes containing 3 ml of 25% sucrose in PBS and centrifuged as above.
- Final virus pellet was resuspended into 10 ml of cold PBS, filtered through the 0.45 ⁇ m filter and kept at 4°C protected from light for further use.
- Virus titer was determined by a plaque assay on Sf9 cells. Virus preparations were analyzed for lipopolysaccharide and bacteriological contaminants. Preparation of recombinant adenoviruses
- Nuclear-targeted LacZ encoding adenoviruses (pCMVnls/acZAd ⁇ ) were constructed and prepared as described by Laitinen et al, supra. Virus preparations were analyzed for replication-competentviruses, lipopolysaccharide and bacteriological contaminants as described by Laitinen et al, Hum. Gene Ther. 9:1481-6 (1998). Gene transfer in vitro
- RAASMC Rabbit aortic cells
- ECV-304 cells human carcinoma/ endothelial cell-like ECV-304 cells
- DMEM serum-free medium
- Viruses were added to medium at MOIs of 200 or 1000, and cells were incubated for 90 min at 37°C.
- growth medium containing 10% fetal bovine serum was added either with or without 10 mM n-butyric acid (Sigma, St. Louis, MD, USA). After 18 h inc ⁇ bation, the media were removed and cells were washed three times with PBS. Cells were fixed with 1.25% glutaraldehyde for 15 min and washed three times with PBS. X-Gal (MBI Fermentas, Lithuania) staining solution (1 mg/ml, 2 mM MgCI 2 , 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 1 x PBS) was added to the cells and incubated for 3 h at 37°C.
- Cells were plated in 96-well plates at a density of 20,000 cells per well in 100 ⁇ L of growth medium consisting of DMEM with 10% fetal bovine serum and antibiotics (100 units/mL of penicillin and 100 ⁇ g/mL of streptomycin). Virus transductions were performed as for the transduction efficiency assay and cells were incubated for 48 h at 37°C. Growth medium was removed and cells were washed with PBS. Serum-free DMEM without phenol red, containing MTT solution (3-(4,5-dimethylthiazolyI-2)-2,5- diphenyl tetrazolium bromide, 5 mg/mL, final concentration 0.3 mg/mi) was then added and cells were incubated for 2 h.
- MTT solution 3-(4,5-dimethylthiazolyI-2)-2,5- diphenyl tetrazolium bromide, 5 mg/mL, final concentration 0.3 mg/mi
- Rabbits were re-anesthetized for gene transfer, which was performed 5 days after the installation of the collar exactly in the same way as described by Laitinen etal (1997), supra, comparing the transfection efficiency of plasmid/liposomes, pseudotyped retroviruses and adenoviruses.
- the collars were opened and filled with 500 ⁇ l of the gene transfer solution containing I x 10 9 pfu of adenovirus or baculovirus.
- the left carotid artery was used for adenovirus and the right carotid artery for baculovirus treatment.
- Four rabbits were killed 3, 7 and 14 days after the gene transfer and arteries were removed for histological analyses. All animal procedures were approved. Histological analysis
- Collared arteries were divided into three equal parts: the proximal third was immersion-fixed in 4% PFA/15% sucrose (pH 7.4) for 4 h, rinsed in 15% sucrose (pH 7.4) overnight and embedded in paraffin.
- the medial part was immersion-fixed in 4% PFA/PBS (pH 7.4) for 30 min, rinsed in PBS (pH 7.2) and embedded in OCT compound (Miles Scientific, Naperville, IL, USA).
- the distal part was snap-frozen in liquid nitrogen and stored at -70°C for mRNA isolation and reverse transcriptase polymerase chain reaction (RT-PCR).
- Paraffin sections were used for immunocytochemical detection of endothelium (CD-31; 1:50 dilution; Dako, Hamburg, Germany), macrophages (RAM-11; 1:100 dilution; Dako), smooth muscle cells (HHF-35; 1:50 dilution; Dako), and T cells (MCA-805; 1:100 dilution; Dako) as described by Yla-Herttuala (1995), supra. Controls for the immunostainings included sections where the first antibody was omitted and sections incubated with class and species matched immunoglobulins.
- RNAse-free DNAse Promega, Madison, Wl, USA.
- M-MulV reverse transcriptase M-MulV reverse transcriptase (MBI Fermentas) was used for cD A synthesis.
- Dynazyme polymerase (Finnzymes, Espoo, Finland) was used for amplification.
- the primers were SEQ ID NO:1 for adenovirus (A) and SEQ ID NO:2 for baculovirus (B) as forward primers, and SEQ ID NO:3 for both as a reverse primer.
- Hot start 95°C 5 min; 58°C 3 min
- 39 cycles each consisting of 95°C 1 min, 58°C 2 min, 72°C 3 min with the final extension of 10 min at 72 °C.
- 5 ⁇ l of the first PCR product was used for the second PCR with forward primers SEQ ID NO:4 (A) and SEQ ID NO:5 (B).
- the reverse primer for both was SEQ ID NO:6.
- the first PCR cycle was 95°C for 5 min followed by 20 cycles as in the first PCR.
- Gene transfer in vitro In order to test the baculovirus stock, RAASMC and ECV-304 cells were transduced at a multiplicity of infection (MOI) of 200 or 1000 pfu per cell in the absence or presence of 10 mM sodium butyrate and the percentage of X-Gal positive cells were counted. The results were compared to cells transduced with /acZ-adenovirus under identical conditions (Table 1). In agreement with published results, (Condreay et al, supra) addition of butyrate to cell cultures increased remarkably the expression of the transgene, especially with baculoviruses.
- MOI multiplicity of infection
- the RAASMC cells seemed to be more susceptible to baculovirus transduction (91 % infected at MO1 1000) than ECV-304 cells (21% infected at MOI 1000).
- Levels of ⁇ -galactosidase activity in the RAASMC cells were also measured by a quantitative biochemical assay with ⁇ -nitrophenyl ⁇ -o- galactopyranoside (ONPG). The results were in line with X-Gal staining showing an increase in the transgene expression after butyrate treatment in the baculovirus- transduced cells.
- ONPG ⁇ -nitrophenyl ⁇ -o- galactopyranoside
- 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-assay was used to measure the cytotoxicity of virus preparations (Table 2). Neither baculoviruses nor adenoviruses showed any major cytotoxicity to RAASMC cells in the absence of butyrate at MOI 200 or 1000. However, together with butyrate, some cytotoxicity was detected in these cells with baculoviruses at a MOI of 1000.
- NZW rabbits were killed 3, 7 and 14 days after gene transfer. Due to the nucleartargeting of the ⁇ -galactosidase expression, intense X-Gal staining was located in the nuclei of the transduced cells. The number of cells positive for ⁇ -galactosidase activity was calculated from the baculovirus-transduced (1 x 10 9 pfu per artery) carotid arteries and was compared with similarly treated adenovirus-transduced arteries. Both viruses mediated delivery of the marker gene to the vessel wall.
- the numbers of transgene positive cells for baculovirus- and adenovirus-treated arteries at day 3 were 12 ⁇ 5 and 23 ⁇ 7 ⁇ -galactosidase positive cells/mm 2 of adventitia (11 ⁇ 4 and 19 ⁇ 6/mm 2 of the whole artery wall), respectively.
- the corresponding values were 17 ⁇ 6 and 22 ⁇ 7 (15 ⁇ 5 and 18 ⁇ 6).
- the values were 0.1 ⁇ 0 and 0.2 ⁇ 0.1 (0.1 ⁇ 0 and 0.1 ⁇ 0.1).
- the baculovirus-mediated gene expression was thus transient with a similar efficiency and time pattern as that of the adenovirus-mediated gene transfer. Transgene expression in the arterial wall was also verified with RT-PCR.
- intima/media ratio (all arteries) was 0.18 ⁇ 0.03 for baculovirus and 0.12 ⁇ 0.01 for adenovirus-treated arteries, which indicates that the procedures did not damage the vessel wall. Histology of the arteries, 7 days after gene transfer, detected no ⁇ -galactosidase activity outside adventitia. For both viruses, macrophage infiltrates and some T cells were detected in the transduced arteries by RAM-11 and MCA-805 immunostainings, respectively. The arterial structure and endothelium remained intact throughout the experiments. Histological findings at all time-points are summarized in Table 3.
- Example 2 Using essentially the same procedure as in Example 1 , it has been shown that baculovirus gene transfer works also in brain and skeletal muscle. Using baculovirus//acZ, rat brain shows positive transfection in various types of brain cells, especially in choroid plexus cells in ventricles and endothelial cells. The profile of transfected cells is clearly different from that of adenoviruses.
- Baculovirus transfection has been demonstrated in rabbit skeletal muscle.
- Baculovirus encoding lacZ (1.8 x 10 10 PFU) was directly injected into the adductor muscle of NZW rabbit via a 25 G needle. The injection volume was 0.5 ml. Tissue samples were collected 7 days after the gene transfer, and X-Gal staining was performed overnight.
- the accompanying drawing illustrates the construction of a nuclear-targeted ⁇ -galactosidase-encoding baculovirus transfection cassette.
- this is a standard public domain baculovirus with polyhedrin promoter, into which have been cloned restriction sites and the CMV-NT lacZ expression cassette.
- the lacZ expression cassette is oriented opposite to the polyhedrin promoter.
- the sequence of the CMV-nt lacZ expression cassette is in SEQ ID NO:7.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001586586A JP2003533992A (en) | 2000-05-26 | 2001-05-29 | Gene delivery by viral vector |
CA002413326A CA2413326A1 (en) | 2000-05-26 | 2001-05-29 | Use of baculovirus vectors in gene therapy |
MXPA02011517A MXPA02011517A (en) | 2000-05-26 | 2001-05-29 | Use of baculovirus vectors in gene therapy. |
EP01931975A EP1283894A1 (en) | 2000-05-26 | 2001-05-29 | Use of baculovirus vectors in gene therapy |
IL15307001A IL153070A0 (en) | 2000-05-26 | 2001-05-29 | Use of baculovirus vectors in gene therapy |
HU0302119A HUP0302119A3 (en) | 2000-05-26 | 2001-05-29 | Use of baculovirus vectors in gene therapy |
AU2001258657A AU2001258657A1 (en) | 2000-05-26 | 2001-05-29 | Use of baculovirus vectors in gene therapy |
PL36028001A PL360280A1 (en) | 2000-05-26 | 2001-05-29 | Use of baculovirus vectors in gene therapy |
US10/478,978 US20040208905A1 (en) | 2001-05-29 | 2002-05-28 | Gene delivery of a viral vector |
CA002448985A CA2448985A1 (en) | 2001-05-29 | 2002-05-28 | Gene delivery via a baculovirus vector |
PCT/GB2002/002504 WO2002096469A2 (en) | 2001-05-29 | 2002-05-28 | Gene delivery via a baculovirus vector |
EP02730459A EP1392837A2 (en) | 2001-05-29 | 2002-05-28 | Gene delivery via a baculovirus vector |
AU2002302780A AU2002302780A1 (en) | 2001-05-29 | 2002-05-28 | Gene delivery via a baculovirus vector |
NO20025657A NO20025657L (en) | 2000-05-26 | 2002-11-25 | Use of Baculovirus Vectors in Gene Therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0012997.3 | 2000-05-26 | ||
GBGB0012997.3A GB0012997D0 (en) | 2000-05-26 | 2000-05-26 | Gene delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001090390A1 WO2001090390A1 (en) | 2001-11-29 |
WO2001090390A9 true WO2001090390A9 (en) | 2003-01-09 |
Family
ID=9892534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/002383 WO2001090390A1 (en) | 2000-05-26 | 2001-05-29 | Use of baculovirus vectors in gene therapy |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1283894A1 (en) |
JP (1) | JP2003533992A (en) |
KR (1) | KR20030072213A (en) |
CN (1) | CN1430675A (en) |
AU (1) | AU2001258657A1 (en) |
CA (1) | CA2413326A1 (en) |
GB (1) | GB0012997D0 (en) |
HU (1) | HUP0302119A3 (en) |
IL (1) | IL153070A0 (en) |
MX (1) | MXPA02011517A (en) |
NO (1) | NO20025657L (en) |
PL (1) | PL360280A1 (en) |
WO (1) | WO2001090390A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9175083B2 (en) | 2004-06-18 | 2015-11-03 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
US11993637B2 (en) | 2007-03-30 | 2024-05-28 | Ambrx, Inc. | Modified FGF-21 polypeptides with non-naturally encoded amino acids |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1392837A2 (en) * | 2001-05-29 | 2004-03-03 | Ark Therapeutics Limited | Gene delivery via a baculovirus vector |
JP4896745B2 (en) | 2004-02-02 | 2012-03-14 | アンブレツクス・インコーポレイテツド | Modified human interferon polypeptides and uses thereof |
US7816320B2 (en) | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
CN101087875B (en) | 2004-12-22 | 2012-08-22 | Ambrx公司 | Compositions of aminoacyl-tRNA synthetase and uses thereof |
US8080391B2 (en) | 2004-12-22 | 2011-12-20 | Ambrx, Inc. | Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer |
CA2927595C (en) | 2004-12-22 | 2023-01-31 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
CN103690936A (en) | 2004-12-22 | 2014-04-02 | Ambrx公司 | Modified human growth hormone |
SG165353A1 (en) | 2005-06-03 | 2010-10-28 | Ambrx Inc | Improved human interferon molecules and their uses |
PT2339014E (en) | 2005-11-16 | 2015-10-13 | Ambrx Inc | Methods and compositions comprising non-natural amino acids |
ES2465473T3 (en) | 2006-09-08 | 2014-06-05 | Ambrx, Inc. | Transcription of arnt suppressor in vertebrate cells |
JP5840345B2 (en) | 2006-09-08 | 2016-01-06 | アンブルックス, インコーポレイテッドAmbrx, Inc. | Modified human plasma polypeptides or modified human Fc scaffold proteins and uses thereof |
JP2010525821A (en) | 2007-05-02 | 2010-07-29 | アンブルックス,インコーポレイテッド | Modified IFN beta polypeptides and their use |
DK2217265T3 (en) | 2007-11-20 | 2017-07-03 | Ambrx Inc | Modified insulin polypeptides and their use |
EP2247743B1 (en) | 2008-02-08 | 2016-04-06 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
BRPI0916515B8 (en) | 2008-07-23 | 2021-07-27 | Ambrx Inc | bovine granulocyte colony-stimulating factor polypeptide (bg-csf), pharmaceutical formulation and composition comprising the same |
CN101358204B (en) * | 2008-08-29 | 2011-05-18 | 浙江理工大学 | Method for preparing cellular membrane and cellular organelle membrane protein after human enveloped virus budding |
BRPI0919031A2 (en) | 2008-09-26 | 2014-09-23 | Ambrx Inc | MICRO-ORGANISMS AND REPLICATION DEPENDENT VACCINES USING NON-NATURAL AMINO ACIDS |
MX346001B (en) | 2008-09-26 | 2017-03-01 | Ambrx Inc | Modified animal erythropoietin polypeptides and their uses. |
CN102753573A (en) | 2009-12-21 | 2012-10-24 | Ambrx公司 | Modified bovine somatotropin polypeptides and their uses |
AU2010341518B2 (en) | 2009-12-21 | 2014-01-09 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
EP4302783A3 (en) | 2010-08-17 | 2024-03-13 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
TWI480288B (en) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
TW201837051A (en) | 2017-02-08 | 2018-10-16 | 美商必治妥美雅史谷比公司 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
CN114736929B (en) * | 2022-05-16 | 2023-06-09 | 睿征医药科技(武汉)有限公司 | Composition, method and application for producing recombinant baculovirus in insect cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU729420B2 (en) * | 1996-11-01 | 2001-02-01 | Eurogene Limited | Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia |
DE19735593C2 (en) * | 1997-08-15 | 1999-08-26 | Hepavec Ag Fuer Gentherapie | Coat protein-modified baculovirus vector for gene therapy |
AU4916299A (en) * | 1998-07-24 | 2000-02-14 | Aventis Pharma S.A. | Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates |
-
2000
- 2000-05-26 GB GBGB0012997.3A patent/GB0012997D0/en not_active Ceased
-
2001
- 2001-05-29 MX MXPA02011517A patent/MXPA02011517A/en unknown
- 2001-05-29 PL PL36028001A patent/PL360280A1/en not_active Application Discontinuation
- 2001-05-29 IL IL15307001A patent/IL153070A0/en unknown
- 2001-05-29 CA CA002413326A patent/CA2413326A1/en not_active Abandoned
- 2001-05-29 JP JP2001586586A patent/JP2003533992A/en active Pending
- 2001-05-29 WO PCT/GB2001/002383 patent/WO2001090390A1/en not_active Application Discontinuation
- 2001-05-29 AU AU2001258657A patent/AU2001258657A1/en not_active Abandoned
- 2001-05-29 HU HU0302119A patent/HUP0302119A3/en unknown
- 2001-05-29 EP EP01931975A patent/EP1283894A1/en not_active Withdrawn
- 2001-05-29 KR KR1020027015961A patent/KR20030072213A/en not_active Application Discontinuation
- 2001-05-29 CN CN01810175A patent/CN1430675A/en active Pending
-
2002
- 2002-11-25 NO NO20025657A patent/NO20025657L/en not_active Application Discontinuation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9175083B2 (en) | 2004-06-18 | 2015-11-03 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
US11993637B2 (en) | 2007-03-30 | 2024-05-28 | Ambrx, Inc. | Modified FGF-21 polypeptides with non-naturally encoded amino acids |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2001258657A1 (en) | 2001-12-03 |
CN1430675A (en) | 2003-07-16 |
CA2413326A1 (en) | 2001-11-29 |
KR20030072213A (en) | 2003-09-13 |
WO2001090390A1 (en) | 2001-11-29 |
HUP0302119A3 (en) | 2005-12-28 |
NO20025657D0 (en) | 2002-11-25 |
GB0012997D0 (en) | 2000-07-19 |
MXPA02011517A (en) | 2004-01-26 |
PL360280A1 (en) | 2004-09-06 |
EP1283894A1 (en) | 2003-02-19 |
IL153070A0 (en) | 2003-06-24 |
NO20025657L (en) | 2002-11-25 |
HUP0302119A2 (en) | 2003-09-29 |
JP2003533992A (en) | 2003-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001090390A9 (en) | Use of baculovirus vectors in gene therapy | |
Airenne et al. | Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery | |
US5880102A (en) | Adenoviral vector system | |
US5871986A (en) | Use of a baculovirus to express and exogenous gene in a mammalian cell | |
AU666142B2 (en) | Viral recombinant vectors for expression in muscle cells | |
US6297220B1 (en) | Adenovirus-medicated gene transfer to cardiac and vascular smooth muscle | |
CA2184065C (en) | Inhibition of arterial smooth muscle cell proliferation | |
JP4733795B2 (en) | Gene therapy using sheep adenovirus vector | |
US6183993B1 (en) | Complement-resistant non-mammalian DNA viruses and uses thereof | |
SK132797A3 (en) | Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis | |
JPH10507927A (en) | Improved adenovirus and uses thereof | |
WO1999006576A1 (en) | A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof | |
AU4340397A (en) | Non-mammalian dna virus having an altered coat protein | |
JP2003501041A (en) | Recombinant adenovirus vector expressing chimeric fiber protein for cell-specific infection and genomic integration | |
AU716748B2 (en) | Conditional expression system | |
WO2001012789A2 (en) | APOLIPOPROTEIN B mRNA-SPECIFIC RIBOZYME | |
US6610534B2 (en) | Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases | |
US20030219412A1 (en) | Somatic gene therapy to suppress secondary cataract formation following eye surgery | |
US20030212030A1 (en) | Novel adenoviral vector for transferring human genes in vivo | |
WO2002096469A2 (en) | Gene delivery via a baculovirus vector | |
KR20010075338A (en) | Use of specific hybrid promoters for controlling tissue expression | |
MXPA97007549A (en) | Viral vectors and their use to treat disordershiperproliferativos, in particular resteno | |
WO2003083122A1 (en) | Treatment and prevention of angiostenosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001931975 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001258657 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2413326 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/011517 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 153070 Country of ref document: IL Ref document number: 1020027015961 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018101755 Country of ref document: CN |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 11, CLAIMS, ADDED |
|
WWP | Wipo information: published in national office |
Ref document number: 2001931975 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027015961 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001931975 Country of ref document: EP |